The global MRSA drugs market size reached US$ 3.6 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 4.5 Billion by 2028, exhibiting a growth rate (CAGR) of 3.6% during 2023-2028. The rising prevalence of antibiotic resistant strains development, continual exposure to multidrug-resistant organisms in healthcare facilities due to prolonged hospital admission and the growing number of clinical trials represent some of the key factors driving the market.
Methicillin-resistant staphylococcus aureus (MRSA) is an infection caused by antibiotic-resistant strains of staphylococcus aureus that generally occurs in patients who undergo surgical procedures, receive intravenous tubing, or come in contact with each other skin-to-skin. The MRSA drugs are used as antimicrobial agents against methicillin-resistant staphylococcus aureus infection in order to kill or restrain it. They inhibit the actions of pathogens while enhancing the patient's cellular synthesis and immunity. The most common MRSA drugs consist of trimethoprim-sulfamethoxazole, clindamycin, minocycline, linezolid, or doxycycline. These drugs are generally used as oral medication, usually on a course of seven to ten days. MRSA infections can arise from hospitals or from community, hence the treatment for MRSA can sometimes involve the administration of oral medications and intravenous (IV) medications, depending on the severity. There are a wide variety of MRSA drugs available that can be used for the treatment of different types of infections, including skin infections, bone infections, bacteremia, and even zoonotic infections in animals.
MRSA Drugs Market Trends:
The rising prevalence of antibiotic resistant strains development among the masses is a significant factor driving the growth of the market. This can be attributed to the increase in the number of cases of hospital-acquired infections (HAIs) on the global level. Also, the continual exposure to multidrug-resistant organisms in healthcare facilities due to prolonged hospital admission is resulting in the development of secondary nosocomial infections, thereby propelling the market. In addition to this, the growing geriatric population that is more susceptible to developing MRSA infections is providing an impetus to the market. Moreover, the augmenting awareness regarding different forms of bacterial infection is leading to a higher uptake of MRSA drugs. In line with this, numerous product innovations, growing number of clinical trials and the introduction of novel drug variants are creating lucrative growth opportunities in the market. However, the high costs involved in developing novel MRSA drug variants is acting as major growth restraining-factor for the market. On the contrary, continual technological developments in various diagnostic tools, along with the increasing number of clinical trial programs for the screening of antibiotic resistant strains of bacteria, are creating a positive market outlook. The market is further impelled by extensive research and development (R&D) activities conducted by the key players. Some of the other factors contributing to the market include the emergence of generic drugs against presently available products, easy availability of antibiotics across online and offline organized platforms, rapid urbanization, and increasing medical expenditure.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global MRSA drugs market, along with forecasts at the global, regional, and country level from 2023-2028. Our report has categorized the market based on MRSA type, drug class, disease indication, route of administration, and distribution channel.
MRSA Type Insights
- Hospital-Acquired (HA-MRSA)
- Community-Acquired (CA-MRSA)
The report has provided a detailed breakup and analysis of the MRSA drugs market based on the MRSA type. This includes Hospital-Acquired (HA-MRSA) and Community-Acquired (CA-MRSA). According to the report, Hospital-Acquired (HA-MRSA) represented the largest segment.
Drug Class Insights
- Folate Antagonist
The report has provided a detailed breakup and analysis of the MRSA drugs market based on the drug class. This includes lipopeptides, oxazolidinones, cephalosporin, tetracycline, folate antagonist, and others. According to the report, lipopeptides represented the largest segment.
Disease Indication Insights
- Skin Infections
- Bone and Joint Infections
- Animal Infections
The report has provided a detailed breakup and analysis of the MRSA drugs market based on the disease indication. This includes skin infections, bone and joint infections, bacteremia, and animal infections. According to the report, skin Infections represented the largest segment.
Route of Administration Insights
- Oral Administration
- Parenteral Administration
The report has provided a detailed breakup and analysis of the MRSA drugs market based on the route of administration. This includes oral administration and parenteral administration. According to the report, parenteral administration represented the largest segment.
Distribution Channel Insights
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
A detailed breakup and analysis of the MRSA drugs market based on the distribution channel has also been provided in the report. This includes hospital pharmacies, retail pharmacies, and online pharmacies. According to the report, hospital pharmacies accounted for the largest market share.
- North America
- Asia Pacific
- South Korea
- United Kingdom
- Latin America
- Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for MRSA drugs. Some of the factors driving the North America MRSA drugs market include the rising medical expenditure, the increasing number of clinical trial programs, extensive research and development (R&D) activities conducted by key players, etc.
The report has also provided a comprehensive analysis of the competitive landscape in the global MRSA drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include AbbVie Inc., Basilea Pharmaceutica Ltd, Crystal Genomics Inc., Cumberland Pharmaceuticals Inc., Melinta Therapeutics Inc, Paratek Pharmaceuticals, Inc., Pfizer Inc, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
|Base Year of the Analysis
|MRSA Types Covered
||Hospital-Acquired (HA-MRSA), Community-Acquired (CA-MRSA)
|Drug Classes Covered
||Lipopeptides, Oxazolidinones, Cephalosporin, Tetracycline, Folate Antagonist, Others
|Disease Indications Covered
||Skin Infections, Bone and Joint Infections, Bacteremia, Animal Infections
|Route of Administrations Covered
||Oral Administration, Parenteral Administration
|Distribution Channels Covered
||Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
|| Asia Pacific, Europe, North America, Latin America, Middle East and Africa
||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
||AbbVie Inc., Basilea Pharmaceutica Ltd, Crystal Genomics Inc., Cumberland Pharmaceuticals Inc., Melinta Therapeutics Inc, Paratek Pharmaceuticals, Inc., Pfizer Inc, etc.
||10% Free Customization
|Report Price and Purchase Option
||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support
||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
Key Questions Answered in This Report:
- How has the global MRSA drugs market performed so far and how will it perform in the coming years?
- What are the drivers, restraints, and opportunities in the global MRSA drugs market?
- What are the key regional markets?
- Which countries represent the most attractive MRSA drugs markets?
- What is the breakup of the market based on the MRSA type?
- What is the breakup of the market based on the drug class?
- What is the breakup of the market based on the disease indication?
- What is the breakup of the market based on the route of administration?
- What is the breakup of the market based on the distribution channel?
- What is the competitive structure of the global MRSA drugs market?
- Who are the key players/companies in the global MRSA drugs market?
Key Benefits for Stakeholders:
- IMARC’s report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the MRSA drugs market from 2017-2028.
- The research study provides the latest information on the market drivers, challenges, and opportunities in the global MRSA drugs market.
- The study maps the leading as well as the fastest growing regional markets. It further enables stakeholders to identify the key country-level markets within each region.
- Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the MRSA drugs industry and its attractiveness.
- Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.